Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.

Haller VL, Cichewicz DL, Welch SP.

Eur J Pharmacol. 2006 Sep 28;546(1-3):60-8. Epub 2006 Jul 25.

PMID:
16919265
2.

Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal delta9-tetrahydrocannabinol.

Cichewicz DL, Welch SP, Smith FL.

Eur J Pharmacol. 2005 Nov 21;525(1-3):74-82. Epub 2005 Nov 8.

PMID:
16288738
3.

Mu and delta opioid-stimulated [35S]GTP gamma S binding in brain and spinal cord of polyarthritic rats.

Cichewicz DL, Cox ML, Welch SP, Selley DE, Sim-Selley LJ.

Eur J Pharmacol. 2004 Nov 3;504(1-2):33-8.

PMID:
15507218
4.

Synergistic interactions between cannabinoid and opioid analgesics.

Cichewicz DL.

Life Sci. 2004 Jan 30;74(11):1317-24. Review.

PMID:
14706563
5.
6.

Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration.

Cichewicz DL, McCarthy EA.

J Pharmacol Exp Ther. 2003 Mar;304(3):1010-5.

7.
8.

Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification.

Cichewicz DL, Martin ZL, Smith FL, Welch SP.

J Pharmacol Exp Ther. 1999 May;289(2):859-67.

Supplemental Content

Loading ...
Support Center